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use#LAAAbstract. The non-essential amino acid neurotransmitter
glycine (Gly) may serve as a biomarker for brain tumors.
Using 36 biopsies from patients with brain tumors [12 glio-
blastoma multiforme (GBM); 10 low-grade (LG), including
7 schwannoma and 3 pylocytic astrocytoma; 7 meningioma
(MN); 7 brain metastases (MT), including 3 adenocarcinoma
and 4 breast cancer] and 9 control biopsies from patients
undergoing surgery for epilepsy, we tested the hypothesis
that the presence of glycine may distinguish among these
brain tumor types. Using high-resolution magic angle spinning
(HRMAS)  1H magnetic resonance spectroscopy (MRS), we
determined a theoretically optimum echo time (TE) of 50 ms
for distinguishing Gly signals from overlapping myo-inositol
(Myo) signals and tested our methodology in phantom and
biopsy specimens. Quantitative analysis revealed higher levels
of Gly in tumor biopsies (all combined) relative to controls;
Gly levels were significantly elevated in LG, MT and GBM
biopsies (P≤0.05). Residual Myo levels were elevated in LG
and MT and reduced in MN and GBM (P<0.05 vs. control
levels). We observed higher levels of Gly in GBM as compared
to LG tumors (P=0.05). Meanwhile, although Gly levels in
GBM and MT did not differ significantly from each other,
the Gly:Myo ratio did distinguish GBM from MT (P<0.003)
and from all other groups, a distinction that has not been
adequately made previously. We conclude from these findings
that Gly can serve as a biomarker for brain tumors and that
the Gly:Myo ratio may be a useful index for brain tumor
classification. 
Introduction
Thus far, brain tumor studies using proton (1H) magnetic
resonance spectroscopy (MRS) have focused mainly on the
absolute concentrations of metabolites, such as choline con-
taining compounds (Cho), N-acetyl aspartate (NAA), and
creatine (Cr), and on their concentration ratios (e.g., Cho/NAA
or Cho/Cr) (1-3). However, there are other metabolites present
in varying concentrations in brain tumors that may provide
useful diagnostic information (4). Indeed a recent in vivo
1H MRS study reported significantly increased levels of
glycine (Gly) in gliomas (5). 
The non-essential amino acid Gly is an important neuro-
transmitter and neuromodulator in the mammalian brain (6). It
also has neurotrophic effects (7) and modulates the metabolism
of microglial cells (8). High levels of Gly have been detected
in brain tumors, especially in glioblastoma multiforme (GBM)
tumors, as well as in the brains of patients with hyper-
glycinemia (3,9-11). In addition, several studies have evaluated
Gly as a potential treatment for schizophrenia (12-14).
While the precise role of Gly in brain tumors is not clear,
its presence is fitting with the hyper-excitable nature of
brain tumors. Given Gly's significance, it would be valuable
to have an accurate measure of Gly in the brain. However
such measurements are difficult because of the presence of
Myo-inositol (Myo), a compound involved in signaling and
in synthesis of inositol-containing-phospholipids (15,16),
since Myo resonances overlap with the CH2-Gly singlet.
Selective Myo and Gly measurement methodologies
using different in vivo 1H MRS filtering techniques have
been described. For example, two-dimensional (2D) J-point
resolved spectroscopy (PRESS) (17) and multiple refocusing
pulses with a very long echo time (TE) (3) have been proposed
for 3 T studies. A TE-averaged PRESS sequence (18) has also
been proposed for 4 T studies. Other methods based on the
differential signal dephasing of Gly and Myo metabolites
have been proposed (19). Mader et al (20) observed a signal
at 3.56 ppm attributable to Gly in long TE spectra and
suggested that discrimination between tumor tissue from
patients with astrocytoma grade II and GBM could be based
on the greater levels of Gly in GBM. Although Mader et al
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301-306.qxd  16/12/2009  01:25 ÌÌ  Page 301results were corroborated (21), other authors using in vivo
1H MRS examinations of gliomas did not attempt to distinguish
between Gly and Myo and interpreted their data as representing
a rise in Myo (1,22). Indeed increased Myo concentrations
were recently reported for a variety of tumors (23). 
Previous studies have indicated that that a reliable sepa-
ration between GBM and metastases cannot be confidently
achieved with 1H MRS alone (24-26). Here, we used ex vivo
high-resolution magic angle spinning (HRMAS) 1H MRS in
order to evaluate the theoretically optimum echo time (TE)
to enable Gly to be distinguished from overlapping Myo
signals and tested our methodology in phantom and biopsy
specimens. We focused on the Gly and Myo signals and
acquired MR spectra with different TE spectra in order to
discriminate amongst different tumor types. 
Materials and methods
Simulated spectra. The simulated spectra were obtained
using the XWINNMR software environment (XWINNMR
version 3.5, Bruker Biospin) under Carr-Purcell-Meiboom-
Gill (CPMG) (27) excitation. 
Phantom. In vitro HRMAS experiments were performed
on a phantom sample (pH 7.0) containing 200 mM Myo
and 200 mM Gly in deuterated water (Sigma Aldrich Inc.,
St. Louis, MO).
Samples. Forty-five control biopsy samples from 9 epileptic
surgeries and 36 tumor biopsies were analyzed. The tumor
biopsies were derived from 12 GBM cases, 10 low-grade
(LG) cases (7 schwannoma and 3 pylocytic astrocytoma), 7
meningioma (MN) cases, and 7 brain metastases (MT) cases
(3 from adenocarcinoma and 4 from breast cancer). Subjects
ranged in age from 17 to 54 years. This study was approved
by our institutional review board.
HRMAS 1H MRS acquisition data. Experiments were per-
formed on a Bruker Bio-Spin Avance NMR spectrometer
(600.13 MHz) using a 4-mm triple resonance (1H, 13C, 2H)
HRMAS probe (Bruker). Specimens were pre-weighed and
transferred to a ZrO2 rotor tube (4 mm diameter, 50 μl), 10 μl
of external standard [trimethylsilyl propionic-2,2,3,3-d4 acid
(TSP), Mw = 172, ‰ = 0.00 ppm) was added and functioned
as a reference both for both resonance chemical shift and
quantification. The HRMAS 1H MRS was performed at 3 kHz
MAS speed and -8˚C (the minimum temperature possible
to minimize tissue degradation). One dimensional (1-D)
water suppressed, fully relaxed spectra were acquired with
an optimized rotor synchronized Carr-Purcell-Meiboom-Gill
(CPMG) pulse sequence [90-(Ù-180-Ù)n-acquisition] (27).
CPMG is preferred over simple free induction decays (FIDs)
since it acts as a T2 filter that reduces the interference of very
broad features in the spectrum baseline, originating from
tissue water and macromolecules. CPMG sequence parameters
were as follows: inter-pulse delay Ù = 2π/ˆr = 400 μs; 256
transients; spectral width of 7.2 kHz; 8 k data-points; and
TR = 3 s. For quantification, we measured the T2 relaxation
time by varying the CPMG evolution time (TCPMG = 2nÙ) [n
from 7 to 800 (~5-480 ms)].
1H HRMAS MRS data processing. MR spectra of specimens
were analyzed using MestReC software (Mestrelab Research,
www.mestrelab.com). A line-broadening apodization function
of 1.0 Hz was applied to CPMG HRMAS 1H FIDs prior to
Fourier transformation (FT). MR spectra were referenced
with respect to TSP at ‰ = 0.0 ppm (external standard),
manually phased, and a Whittaker baseline estimator was
applied to subtract the broad components of the baseline.
MRS-derived metabolite quantification. Concentrations of
Gly and Myo metabolites were calculated using MestReC
software (Mestrelab Research, http://www.mestrelab.com). An
automated fitting routine based on the Levenberg-Marquardt
algorithm (28,29) was applied after manual peak selection,
adjusting peak positions, intensities, linewidths and Lorentzian/
Gaussian ratio until the residual spectrum was minimized.
Metabolite concentration (in μmol/g) was calculated using
the following equation:
Mass TSP Met peak area NTSP 1000 g/kg
––––––––––––– x ––––––––––– x ––––– x ––––––––––
Mol weight (TSP) TSP peak area NMet Sample weight
where mass TSP was constant (μg), the molecular weight
(mol weight) of TSP was 172.23 g/mol; Met, metabolites;
NTSP was the TSP proton number (9 1H), and NMet was the
metabolite proton number (30).
Statistical analysis. Statistical analysis was performed using
the Student's t-test: paired two sample for means. P-values
<0.05 were considered statistically significant.
Results
Theoretical. Six CH groups form the Myo metabolite generate
a complex spectral pattern in the 1H spectrum and can be
modeled as an AM2N2P spin system. According to the spin
system, the six protons have different resonances: the M
protons resonate at 3.53 ppm (M2), the N resonates at 3.61 ppm
(N2), and the A and P protons resonate at 4.07 and 3.28 ppm,
respectively. On the contrary, the two protons of Gly constitute
a singlet at 3.55 ppm. The Gly singlet overlaps with the
strongly coupled resonances of Myo at 3.53 ppm (M2). The
J-coupling constant between the M2 and N2 protons is 9.9 Hz.
As TE increases, J-coupling introduces a dephasing in the M2
resonance due to the large J-coupling constants, which can be
exploited for detecting the Gly singlet (19). Fig. 1 shows 1H
CPMG HRMAS simulated spectra acquired at varied TEs
(single coherence). The spectrum acquired at TE = 10 ms did
not exhibit J-modulation, but at TE = 50 ms, we detected a
strong Gly peak and a reduction of the Myo doublet at
3.53 ppm without loss of signal. This was possible because
of the large J-coupling (9.9 Hz) of the Myo proton signal at
3.53 ppm and its fast J-modulation. The two protons of Gly
constitute a singlet at 3.55 ppm and, like all singlets, it does not
have phase modulation during the spin-echo single excitation.
When we used a single spin-echo coherence, the signal of
Myo at 3.53 ppm underwent rapid J-modulation, and at TE =
100 ms, the intensity of the Myo resonance was strongly
reduced. At longer TEs (i.e., TE = 300 ms), we detected the
Gly singlet but observed a general reduction of the signal in
the spectrum due to T2 relaxation.
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HRMAS experiments on the phantom using 1D CPMG
sequence. Our acquisitions ranged from 5 to 480 ms. We thus
followed the reduction of Myo signals in favor of the Gly
singlet. The Myo signals appeared in phase at a TE of 50 ms,
but were reduced with respect to the signals at a TE of 10 ms
(not all 1H magnetization components were reported in phase
for the acquisition). Meanwhile the Gly signal was readily
detectable and independent from the Myo signals. When we
performed long TE experiments, the Myo signal was further
reduced, but the Gly signal was also lost. At a TE of 50 ms,
the signal intensity of Myo showed a 50% decrease due to J-
modulation. 
As illustrated in Figs. 3 and 4, we demonstrated that
detection of Gly in brain tumor biopsies is feasible using
HRMAS 1H MRS at a TE of 50 ms with CPMG. All spectra
were scaled with respect to TSP signal (not shown in figures).
The results from the brain biopsies were similar to the phantom
data (Fig. 2). Fig. 3 shows MR spectra obtained from brain
metastasis samples using 1D CPMG at 3 different TEs. The
MT samples showed greater overlap between Myo signals
and the Gly singlet at a TE of 10 ms; but when we applied a
TE = 50 ms, the Myo signal was greatly reduced and it was
possible to obtain a better quantification of Gly metabolites.
Using a longer TE (i.e., 300 ms), all metabolite resonances in
the spectrum, including the Gly resonance, were reduced. 
Fig. 4 shows mean spectra for each tumor type at a TE of
50 ms. The Myo resonance (3.53 ppm) decreased as the TE
was increased, and this permitted better Gly detection for
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Figure 1. Simulated spectra of Gly (3.55 ppm) and Myo (3.53 ppm M2 H)
under single spin-echo excitation. From left to right: simulated spectral line
shape at TEs of 10, 50 and 100 ms. Spectra were simulated in the XWINNMR
software environment.
Figure 2. In vitro experimental 1D CMPG 1H HRMAS spectra of Gly and
Myo. The Gly singlet is at 3.55 ppm, the Myo M2 doublet is at 3.53 ppm, and
the Myo N2 triplet is at 3.61 ppm.
Figure 3. 1H MR spectra using CPMG from brain metastases obtained at
three different TEs. The Gly singlet was detected at 3.55 ppm, and the Myo
signals at 3.53, 3.61 and 4.07 ppm. This is a situation where it is important
to separate Gly from the overlapping Myo signals since both Gly and Myo
are detected at high concentrations (Table I).
Figure 4. HRMAS 1H MR spectra using CPMG in control and brain tumor
biopsies acquired with a TE of 50 ms. The Gly singlet at 3.55 ppm is labeled.
MR spectra are scaled with respect to TSP signal (not shown here).
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Myo signal dominated the Gly signal. Meanwhile in LG
brain tumors, Gly peaks were detectable in spite of the
presence of persistent Myo signals. The Gly signal was readily
detectable, and almost entirely separate from Myo signals, in
the spectra from the other tumor types. 
The amounts of Gly and Myo and the Gly:Myo ratios
calculated from the CPMG spectra (TE = 50 ms) of control
(C) and brain tumor biopsies are summarized in Table I
and Fig. 5. Gly levels in all brain tumor types considered as a
group were increased relative to control levels. Separate
analysis of the different tumor type groups revealed that
the mean Gly levels in LG, MT and GBM specimens were
significantly higher than control Gly levels (P<0.05). On the
other hand, Myo was decreased in GBM and MN tumors
relative to control levels (P<0.05). 
The mean Gly level in GBM tumors was 67.44% higher
than that in LG tumors (P=0.05) and 138.72% higher than
that in MN tumors (P=0.01), but did not differ significantly
from that in MT tumors (GBM value 10.21% higher, P=0.65
vs. MT). Meanwhile, the mean Myo level in GBM tumors
was 92.63% lower than that in LG tumors (P=0.001) and
89.51% lower than that in MT tumors (P=0.0005), but did
not differ significantly from that in MN tumors (GBM value
33.17% lower, P=0.465 vs. MN). 
The distinction between control and brain tumor biopsies
could easily be recognized in observing the relative Gly and
Myo levels. The mean Gly:Myo ratio was higher in GBM
relative to that in controls (P=0.0004) as well as to the mean
ratios of the other tumor types (P≤0.05). The mean Gly:Myo
ratio in MN was also higher than the mean control value
(P=0.02). It is particularly noteworthy that the mean Gly:Myo
ratio for GBM was 889% that for MT (P=0.003), a difference
that enabled MT and GBM to be readily distinguishable
based on their different Gly:Myo ratios (Fig. 5). 
Discussion
The present study demonstrates that our theoretically and
experimentally optimal MRS protocol can be used to detect
increased Gly and attenuated Myo in brain tumors. We further
demonstrated that the ratio of Gly and Myo detected can be
used to discriminate between certain tumor types, namely
GBM and MT. A principal finding of our study was that
detection of Gly in brain tumor biopsies is feasible using
HRMAS 1H MRS at a TE of 50 ms with CPMG. We
demonstrated the importance of distinguishing Gly from
Myo when both metabolites are present at high levels (Fig. 3). 
We chose a TE at which the Myo resonance was suf-
ficiently attenuated to allow for optimal Gly detection. If
we were to acquire for a longer period of time, we would
probably obtain even lower amounts of Myo, but we would
also start to lose the Gly signal. We believe that the present
tumor classification approach has the advantage of simplicity
and is advantageous in terms of not requiring a long time for
MR spectral acquisition or sample preparation. Indeed,
other approaches (3,17,18) involving data acquisition at
long TEs may suffer from substantial signal losses because
with increasing magnetic field strength, the Hahn relaxation
time T2 of metabolites decreases at high magnetic fields
(due to an increased dynamic dephasing contribution). Other
methods based on the differential signal dephasing of Gly and
Myo that may provide relatively better ability to discriminate
healthy brain from brain tumors (19,20) have the probable
disadvantage of being time consuming in vivo. 
Our results showing that we can differentiate brain tumor
types based on the amount of Gly and Myo they contain are
in agreement with prior observations (31-33). Indeed, the
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Table I. Concentration of Gly, residual myo-inositol, and
Myo:Gly ratio in μmol/g from CPMG spectra (TE = 50 ms)
in control and brain tumor biopsies.
–––––––––––––––––––––––––––––––––––––––––––––––––
Biopsies Gly Myo Gly/Myo
–––––––––––––––––––––––––––––––––––––––––––––––––
Control
n=9 0.99±0.34a 1.85±0.30 0.54±0.18
LG
n=10 2.81±0.60 4.25±0.58 0.69±16
% change from C +183.84 +129.73 +27.78
P-valueb 0.050 0.04 0.25
MN
n=7 1.70±0.38 0.46±0.15 3.70±1.07
% change from C +71.72 -75.14 +585.19
P-value 0.194 0.001 0.02
MT
n=7 3.07±0.28 2.78±0.31 1.33±1.07
% change from C +210.10 +50.27 +146.30
P-value 0.0003 0.032 0.03
GBM
n=12 4.08±0.57 0.31±0.14 13.16±2.24
% change from C +312.12 -83.24 +2,337.04
P-value 0.001 0.0001 0.0004
–––––––––––––––––––––––––––––––––––––––––––––––––
aValues are means ±SE; bStudent's t-test; ND.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 5. Gly and Myo levels distinguish control from brain tumor biopsies.
Note that the major metabolite in GBM tumors was Gly whereas MT tumors
contained substantial amounts of Myo. These data provide a clinically
important distinction between MT and GBM.
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relative amounts of Gly and Myo (Fig. 5). In agreement with
others, we found more Myo in brain tumors than in controls.
Indeed, as reported previously (23), we found that Myo was
the predominant metabolite over Gly in LG tumors. Such
findings may implicate Myo as a marker for tumor malignancy;
Myo has also been suggested to be an indicator of reactive
astrogliosis (22,23) and of potential astrocytic tumor pro-
liferation rate (34). 
Our finding of less Myo in GBM relative to control speci-
mens, however, would be inconsistent with using Myo as a
general brain tumor marker. With the data currently available,
we cannot definitively explain this discrepancy. It is possible
that, in other studies, much of the Gly signal was mis-inter-
preted as Myo signal due to the overlap between the signals.
Our data are in agreement with Castillo et al (31) of
decreased Myo in GBM relative to controls. However, in the
same study, Castillo et al found higher Myo levels in LG
relative to controls. They explained their findings by
suggesting that a lack of activation of the phosphatidylinositol
pathway leads to an increased Myo pool in LG tumors that
is visible by MRS (31). Thus, we believe that with Gly as
a marker for tumor malignancy and Myo as a marker for
astrogliosis, distinction between these two metabolites should
provide information pertinent to tumor metabolism that is
valuable for diagnosis and monitoring of treatment. 
We distinguished MN tumors, which had a high Gly:Myo
ratio, from LG tumors that had an inverse Gly:Myo ratio
(low Gly, high Myo) relative to MN tumors. A low Gly:Myo
ratio also distinguishes MT from other tumors, especially
GBM, which had the highest ratio of all tumor types
examined in this study. The ability to distinguish high-grade
gliomas such as GBM from other tumor types (33),
especially MT tumors, is clinically important given that our
ability to make this distinction is currently inadequate (35).
This distinction was not made successfully in a previous study
in which GBM and MT were combined into a single group;
the authors concluded that a reliable separation between
high-grade brain tumors and metastasized tumors cannot be
confidently achieved using single voxel 1H MRS spectroscopy
alone (24-26,35). Here, we demonstrated that reduced Myo
together with high Gly can distinguish between GBM and
MT, which both exhibit intense, high level Gly signals. 
Although our study was performed in brain tissue biopsies
ex vivo, our approach because of its simplicity, can be easily
implemented in high magnetic field clinical scanners in vivo,
where time constraints are an issue. In the future, in vivo MR
imaging of gene transcription, when approved for humans,
may be an even faster and more specific approach in this
regard (36). In fact, in our hands, the gene cd133, a stem cell
marker for malignant brain tumors (37), seems to be able to
discriminate between primary tumors (high or low grade)
and metastasized tumors (unpublished data). Thus, in vivo
MR imaging of the cd133 gene product may offer a robust
clinical approach that could complement the approach proposed
herein. Simultaneous MR and positron emission tomography
imaging, which is already feasible in humans, is also opening
up new possibilities in this area (38).
In conclusion, we demonstrated that by distinguishing
Gly from the overlapping Myo signals, we could reliably
distinguish between tumor types. The relative presence of
Gly and Myo enabled us to distinguish high-grade gliomas
from metastasized tumors, a distinction not adequately made
at present. We propose that Gly can serve as a useful biomarker
in brain tumors. 
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